Heather Harte-Hall
About Heather Harte-Hall
Heather Harte-Hall is Chief Compliance Officer at Cabaletta Bio. She joined Cabaletta in March 2019 and was promoted from Vice President of Quality and Compliance to Chief Compliance Officer on November 9, 2021 . She previously led Clinical Quality and Compliance at Adaptimmune and held quality/compliance roles at Centocor, Wyeth, and Pfizer; she holds an M.S. in Psychology (Capella University) and a B.A. in Business Administration (St. Leo University) . She is active in industry organizations (ARM Accelerator Group; SCCE; also listed with RQA) . Company context during her tenure: Cabaletta reported no revenue in 2023–2024 and disclosed Pay-vs-Performance TSR values of $245.41 (2023) and $24.54 (2024) for a $100 initial investment; net income (loss) was $(67.68) million (2023) and $(115.86) million (2024) .
Past Roles
| Organization | Role | Dates | Strategic impact |
|---|---|---|---|
| Cabaletta Bio | Chief Compliance Officer | Appointed Nov 9, 2021 | Leads enterprise compliance program supporting clinical development and manufacturing expansion . |
| Cabaletta Bio | VP, Quality & Compliance | Mar 2019–Nov 2021 | Built quality/compliance programs focused on risk management, regulatory monitoring, auditing, and policy/process alignment . |
| Adaptimmune Therapeutics | Head of Clinical Quality & Compliance | Prior to 2019 | Built clinical compliance program and culture of integrity for ethical clinical conduct . |
| Centocor Biotech; Wyeth; Pfizer | Quality/Compliance roles | Prior roles | Various roles in pharmaceutical quality and compliance management . |
External Roles
| Organization | Role | Details |
|---|---|---|
| Alliance for Regenerative Medicine (ARM) | Committee Member (Accelerator Group) | Ongoing industry engagement in regenerative medicine compliance/quality topics . |
| Society of Corporate Compliance and Ethics (SCCE) | Member | Professional compliance network participation . |
| Research Quality Association (RQA) | Listed as member (profile) | Additional external engagement noted in third-party profile . |
Fixed Compensation
- Not individually disclosed for Ms. Harte-Hall in Cabaletta’s DEF 14A filings (named executive officers are the CEO, President Science & Technology, and CMO). She is not listed in the Summary Compensation Tables, indicating her compensation is not reported as a NEO .
Performance Compensation
- Cabaletta’s executive annual incentive plan (applies to executives including the CCO) is based on company objectives (pipeline, manufacturing/clinical/compliance processes, financing/BD milestones, culture) plus individual performance; no award weightings or specific CCO payout details are disclosed .
2020 Annual Bonus Outcomes (NEO program context)
| Item | Value |
|---|---|
| Company achievement | 110% |
| Individual achievement (CEO) | 120% |
| Individual achievement (Binder) | 120% |
| Individual achievement (Chang) | 130% |
2022 Annual Bonus Outcomes (NEO program context)
| Item | Value |
|---|---|
| Company achievement | 109% |
| Individual achievement (CEO) | 125% |
| Individual achievement (Binder) | 115% |
| Individual achievement (Chang) | 110% |
2023 Annual Bonus Outcomes (NEO program context)
| Item | Value |
|---|---|
| Company achievement | 107% |
| Individual achievement (CEO) | 119% |
| Individual achievement (Binder) | 120% |
| Individual achievement (Chang) | 120% |
- Long-term incentives are stock options (no RSUs/PSUs disclosed for executives in 2023–2024), reinforcing upside alignment; the proxy emphasizes options as the primary LTI vehicle .
Equity Ownership & Alignment
- Individual beneficial ownership for Ms. Harte-Hall is not itemized in the Principal Stockholders tables; she is not listed among named executive officers or directors with disclosed individual holdings in 2024–2025 proxy tables .
- Group alignment context: as of April 28, 2025, all executive officers and directors as a group (11 persons) beneficially owned 6,213,257 shares (11.25%) out of 50,743,101 shares outstanding .
- Hedging/pledging: Insider trading policy expressly prohibits short sales, derivative/hedging transactions, and pledging/margining of company stock; any waiver would require Audit Committee approval (none reported) .
- Clawback: A Dodd-Frank compliant Compensation Recovery Policy was adopted on September 12, 2023, requiring recoupment of excess incentive compensation after a restatement for covered executives .
Employment Terms
- The company discloses that named executive officers are employed at will; specific employment agreement terms, severance, or change-of-control provisions are explicitly described only for certain NEOs (e.g., CEO) and are not provided for the CCO in the proxy .
- Insider trading and 10b5-1 plan governance are detailed in policy (pre-clearance required; additional 10b5-1 constraints) .
Performance & Company Context
| Metric | 2023 | 2024 |
|---|---|---|
| TSR – value of $100 initial investment (year-end) | $245.41 | $24.54 |
| Net Income (loss), $mm | $(67.68) | $(115.86) |
| Revenue | Company disclosed no revenue in 2023 and 2024 | Company disclosed no revenue in 2023 and 2024 |
The proxy’s Pay-vs-Performance section notes the company does not use net income as a performance measure given pre-commercial status; incentives are tied to operational/pipeline objectives .
Vesting Schedules and Insider Selling Pressure
- No individual Form 3/4 filings citing “Heather Harte-Hall” were identified via the company’s Section 16 filings list during this review; further direct EDGAR name queries may be warranted to confirm if any were filed under variant name formats .
- With hedging/pledging prohibited and no identified personal insider sales filings, near-term selling pressure signals tied to her holdings are not evident from available disclosures .
Related Party Transactions and Governance
- The company reports no related-party transactions over $120,000 since January 1, 2021 outside of ordinary compensation arrangements disclosed elsewhere .
- Governance and risk oversight include formal insider trading controls and a board Science & Technology Committee overseeing R&D/manufacturing since 2023 .
Investment Implications
- Compensation alignment: Executive incentives focus on pipeline, manufacturing, compliance execution, financing/BD, and culture—key value drivers for a pre-revenue cell therapy developer. Options-heavy LTIs (vs. RSUs) increase upside alignment but also risk if milestones slip .
- Retention and trading signals: No individual ownership or Form 4 data for Ms. Harte-Hall were identified; combined with prohibitions on hedging/pledging and a formal clawback, governance risk appears contained from a compliance-leadership standpoint .
- Execution risk context: Company TSR was highly volatile between 2023 and 2024; negative net income reflects pre-commercial investment cycle—placing a premium on regulatory, clinical, and manufacturing compliance where the CCO function is critical to de-risk timeline execution .
- Bottom line: While Ms. Harte-Hall’s individual pay and holdings are not disclosed, her remit (compliance/quality) aligns with risk mitigation in clinical operations and manufacturing scale-up. From an equity perspective, absence of pledging and lack of observed insider selling filings reduce alignment concerns, and the option-centric incentive framework at the company favors long-term value creation if milestones continue to be met .